CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq: CAMP) announced an inducement option grant on February 16, 2026 to a newly hired employee. The company granted a non-qualified stock option for 8,000 shares with a 10-year term and an exercise price of $3.85, equal to the closing price on the grant date.
The option vests over four years: 25% on the first anniversary and the remainder in 36 equal monthly installments, subject to continued service, under an Inducement Option Award Agreement.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CAMP
On the day this news was published, CAMP gained 4.15%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $10M to the company's valuation, bringing the market cap to $254.74M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CAMP’s price change of 0.11% was minimal while momentum-screened biotech peers like GANX, MAIA, and PYPD were moving up. Broader biotech strength did not translate into a notable move in CAMP around this small inducement grant.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 16 | Inducement option grant | Neutral | -21.0% | Single-employee inducement option for 8,000 shares with 10-year term. |
| Jan 06 | Conference appearance | Neutral | +0.0% | Planned corporate update at J.P. Morgan Healthcare Conference. |
| Dec 18 | Equity offering | Negative | -12.9% | Pricing of 5,000,000-share offering at $6.00 for $30M gross proceeds. |
| Dec 18 | GSK collaboration | Positive | -12.9% | Strategic ASO collaboration with GSK with $17.5M upfront and milestones. |
| Dec 12 | Inducement grants | Neutral | +4.0% | Board-approved inducement options totaling 92,000 shares to four new hires. |
Recent material financings and a major GSK collaboration were followed by negative price reactions, while routine inducement grants have produced mixed or divergent moves.
Over the last six months, CAMP has combined strategic and financing activity with routine HR-related equity grants. On Dec 18, 2025, it announced a $30.0 million underwritten offering at $6.00 and a separate GSK collaboration with $17.5 million upfront and up to $440 million in milestones, both followed by -12.9% moves. Multiple inducement option grants in Dec 2025 and Jan 2026 involved small option awards and drew varied reactions, while a J.P. Morgan conference appearance on Jan 14, 2026 saw no meaningful price change.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 10, 2025 registers up to $300,000,000 of securities and includes an at-the-market component of up to $100,000,000. It has already been used in connection with a 424B5 underwritten offering and a 424B3 resale registration, indicating an established mechanism for future capital raises.
Market Pulse Summary
This announcement details a modest inducement stock option of 8,000 shares at a $3.85 exercise price, vesting over 4 years under Nasdaq Listing Rule 5635(c)(4). It follows a series of similar grants and larger capital actions, including a $30.0 million offering and a $300,000,000 Form S-3 shelf with ATM capacity. Investors evaluating this news in context may focus more on the company’s broader financing tools, past price reactions to offerings, and upcoming clinical milestones than on this small HR-related grant.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock option financial
exercise price financial
vesting financial
inducement option award agreement regulatory
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on February 16, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Inducement Grant has a ten-year term and an exercise price per share of
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
